Verition Fund Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Verition Fund Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,771	Closed	-$588K	–	2786
2023 Q2	$588K	Hold	5,771	–	–	0.01%	1147
2023 Q1	$525K	Buy	+5,771	New	+$339K	0.01%	1205
2022 Q2	–	Sell	-83,158	Closed	-$2.72M	–	3239
2022 Q1	$2.72M	Buy	+83,158	New	+$2.47M	0.03%	745

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's RETA Position: Q3 2023 in Review

Verition Fund Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,771 shares — an estimated $588K sold.

Verition Fund Management first reported a position in RETA in Q1 2022 and held it in 3 quarters. The position peaked at $2.72M in Q1 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Verition Fund Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Verition Fund Management sold 5,771 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $588K.
Verition Fund Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 3 quarters.
Verition Fund Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.72M in Q1 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.